BiotechTube
Curia

Curia

Paris, France· Est.
curiaglobal.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Curia is a global, full-service CDMO with a significant footprint, operating 23 facilities across North America, Europe, and India with an estimated 3,500 employees. Founded in 2021 as a new entity, it leverages a legacy of over three decades of experience in the industry, offering comprehensive capabilities in drug discovery, development, and manufacturing. Its business model is purely service-based, catering to a diverse clientele from small biotechs to large pharma, and it is a revenue-generating private company. The firm's strategy is built on deep scientific expertise, a collaborative partnership model, and a flexible, scalable global network.

Drug DeliveryGeneric DrugsMicrobiomeSmall Molecules

Technology Platform

Integrated global CDMO platform offering drug discovery, development, and manufacturing services across Small Molecules, Generic APIs, Biologics (including fermentation), and Sterile Drug Product (including high-potency and cytotoxic fill-finish).

Opportunities

The growing trend of biopharma outsourcing and increasing complexity of drug modalities (e.g., biologics, sterile injectables) drives demand for full-service, expert CDMOs.
Curia's global footprint and integrated service model allow it to capture more value per client program and serve a diverse range of companies from small biotechs to large pharma.

Risk Factors

Key risks include operational/quality failures at its global facilities, intense competition in the CDMO sector pressuring margins, and regulatory compliance risks across multiple jurisdictions.
Its financial performance is also tied to the success and outsourcing decisions of its client base.

Competitive Landscape

Curia operates in a highly competitive global CDMO market with large players like Lonza, Catalent, and Thermo Fisher Scientific, as well as numerous specialized and regional competitors. Its differentiation is based on its integrated end-to-end services, specific expertise in sterile fill-finish and complex APIs, and a flexible partnership model backed by a 30-year legacy.

More companies in Small Molecule Drugs →More companies in France →